Rene M. Overmeer

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond.

Accelerating personalized medicine: miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond.

Journal: npj biomedical innovations

Published: June 24, 2025

Single-cell multi-omics characterize colorectal tumors, adjacent healthy tissue and matched (tumor) organoids identifying CRC-unique features.

Single-cell multi-omics characterize colorectal tumors, adjacent healthy tissue and matched (tumor) organoids identifying CRC-unique features.

Journal: International journal of cancer

Published: December 13, 2024

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.

Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 20, 2023

Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules.

Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: January 30, 2023

Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.

Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.

Journal: Journal of visualized experiments : JoVE

Published: May 17, 2021

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.

Journal: Cell reports

Published: March 02, 2021

Live imaging of cell division in 3D stem-cell organoid cultures.

Live imaging of cell division in 3D stem-cell organoid cultures.

Journal: Methods in cell biology

Published: June 30, 2018

Corrigendum: Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.

Corrigendum: Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.

Journal: Nature medicine

Published: November 09, 2017

Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.

Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.

Journal: Nature medicine

Published: August 08, 2016

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

Journal: eLife

Published: June 05, 2016

Sequential cancer mutations in cultured human intestinal stem cells.

Sequential cancer mutations in cultured human intestinal stem cells.

Journal: Nature

Published: November 11, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026